Literature DB >> 2522159

Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples.

D H Feeny1, G W Torrance.   

Abstract

The utility approach to the measurement of health-related quality of life is discussed and its theoretical foundations and compatibility with economic evaluation are explained. The advantages of the approach include its generalizability, comprehensiveness, ability to integrate mortality and morbidity effects, ability to represent multiple viewpoints, and its incorporation of time and risk preferences in the scores. Disadvantages include interviewer administration, limitations on obtaining scores from all types of subjects, some lack of precision, and attenuated clinical sensibility. Use of the utility approach as an outcome measure in two recent clinical trials is also described. In a trial of an oral gold compound for arthritis, the utility measures were responsive and added information to that from standard clinical and other quality-of-life measures. The utility approach and clinical decision making are being used in an on-going trial of two procedures for prenatal diagnosis in which major potential differences include quality-of-life effects. The comprehensiveness of the utility approach overcomes difficulties in interpreting results from more narrowly focused psychosocial measures of outcome. In sum, the utility model provides a reliable, valid, and responsive approach to measuring quality of life as an outcome in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522159     DOI: 10.1097/00005650-198903001-00016

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  32 in total

Review 1.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 2.  The use of QALY and non-QALY measures of health-related quality of life. Assessing the state of the art.

Authors:  M Deverill; J Brazier; C Green; A Booth
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  Measurement of short term health effects in economic evaluations.

Authors:  A M Holmes
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

4.  Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients.

Authors:  Francis S Lobo; Cynthia R Gross; Barbara J Matthees
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

5.  The stability of utility scores: test-retest reliability and the interpretation of utility scores in elective total hip arthroplasty.

Authors:  D Feeny; C M Blanchard; J L Mahon; R Bourne; C Rorabeck; L Stitt; S Webster-Bogaert
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

6.  Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease.

Authors:  Holger J Schünemann; Roger Goldstein; M Jeffery Mador; Douglas McKim; Elisabeth Stahl; Lauren E Griffith; Ahmed M Bayoumi; Peggy Austin; Gordon H Guyatt
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

7.  French cross-cultural adaptation of the Health Utilities Indexes Mark 2 (HUI2) and 3 (HUI3) classification systems. Clinical and Economic Working Groups.

Authors:  N Costet; C Le Galès; C Buron; F Kinkor; M Mesbah; J Chwalow; G Slama
Journal:  Qual Life Res       Date:  1998-04       Impact factor: 4.147

Review 8.  Quality of life measures in cancer chemotherapy: methodology and implications.

Authors:  P A Ganz
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

9.  Assessing health-related quality of life in cataract patients: the relationship between utility and health-related quality of life measurement.

Authors:  J E Lee; P J Fos; M A Zuniga; P R Kastl; J H Sung
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

Review 10.  Methods for assessing relative importance in preference based outcome measures.

Authors:  R M Kaplan; D Feeny; D A Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.